Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Source:http://linkedlifedata.com/resource/pubmed/id/17932248

Blood 2008 Feb 1 111 3 1039-43

Download in:

View as

General Info

PMID
17932248